To date, Agencies from the
'It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favorable terms to support the Company's continued development, and this latest funding takes the total non-dilutive funding to-date from all sources to over
Dr.
About the Funding
The grant of approximately
The unsecured loan of approximately
The unsecured loan of approximately
The repayment terms are also split into 2 parts: repayment independent of revenues (limited to 30% from 2023 to 2034) and repayment revenue dependent at 2.89% of revenue generated on this product from launch up to 2032.
Namur Invest provided a loan of approximately
About Volition
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in
Safe Harbor Statement
Statements in this press release may be 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'aims,' 'targets,' 'believes,' 'seeks,' 'estimates,' 'optimizing,' 'potential,' 'goal,' 'suggests,' 'could,' 'would,' 'should,' 'may,' 'will' and similar expressions identify forward-looking statements. These forward-looking statements relate to the use of proceeds from the additional funding, the effectiveness of Volition's blood-based diagnostic and prognostic tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the
Pursuant to the disclosure requirements of the NYSE American Company Guide Section 711(a), Volition is reporting that its Compensation Committee of its Board of Directors has approved the issuance of a warrant to purchase up to 125,000 shares of Volition common stock (the 'Warrant') to Mr. Gael Forterre as a material inducement for his entering employment as the Vice President of Sales of Volition's wholly-owned subsidiary,
Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of
Contact:
Tel: +44 (0)7557 774620
Email: mediarelations@volition.com
(C) 2021 Electronic News Publishing, source